Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This trial is testing two novel combinations (temozolomide plus osimertinib OR temozolomide
plus lorlatinib) which have not been evaluated in clinical trials. Thus, the exact benefits
of these novel combinations are unclear. However, based on the mechanism of action of
temozolomide and CNS(Central Nervous System) penetration/activity in other tumor types, it is
hypothesized that adding temozolomide to osimertinib or temozolomide to lorlatinib may
provide improvement in CNS disease control in patients with CNS progression on either of
these latter two TKIs (Tyrosine kinase inhibitors).